Election 2014
SENSEX NIFTY

Fda

Apr 09, 2014 at 14:20 | Source: Moneycontrol.com
Lupin announced today that it has received final approval for its Pioglitazone Tablets USP, 15 mg, 30 mg, and 45 mg from the United States Food and Drugs Administration (FDA) to market a generic version of Takeda Pharmaceuticals USA, Inc.s (Takeda) Actos Tablets, 15 mg, 30 mg, and 45 mg.
Apr 07, 2014 at 10:31 | Source: Moneycontrol.com
The first question facing observers would be whether Sun would be able to help Ranbaxy get past its troubles with the US FDA, which has now stopped imports into the US from all four of its manufacturing plants in India.
Apr 07, 2014 at 09:13 | Source: CNBC-TV18
According to Ajay Piramal, Chairman of Piramal Group, Daiichi couldn't handle FDA issues faced by Ranbaxy but Sun is competent to handle these issues.
Apr 07, 2014 at 08:45 | Source: Moneycontrol.com
Ranbaxy Laboratories has informed that United States Attorney's Office for the District of New Jersey has issued an administrative subpoena dated March 13, 2014 to Ranbaxy seeking information primarily related to the Company's API Toansa manufacturing facility in India for which a Form 483 was issued by FDA culminating into import alert.
Apr 03, 2014 at 14:46 | Source: Reuters
Drugs made at the plant, based in Bangalore, will be detained without physical examination because the factory did not meet the FDA's good manufacturing practices, the agency said on its website on Wednesday.
Apr 03, 2014 at 10:29 | Source: CNBC-TV18
Anmol Ganjoo, VP-institutional equities, JM Financial says the recent spate of good news has led the market to believe that the issues face by the pharma sector may be on the mend.
Apr 01, 2014 at 19:16 | Source: PTI
Copaxone (Glatiramer Acetate) is used in the treatment of relapsing-remitting multiple sclerosis. Last year, US Court of Appeals for the Federal Circuit reversed a district court's earlier finding related to Teva's US Patent for the drug.
Mar 28, 2014 at 17:02 | Source: Moneycontrol.com
The move is positive for Ranbaxy because they are discussing about Lipitor and how FDA should study copy cat drugs more keenly because patients dont react to them sometimes.
Mar 26, 2014 at 08:42 | Source: Reuters
In the short term, that is expected to benefit larger global competitors, such as Teva Pharmaceutical Industries Ltd, Actavis Plc and Mylan Inc, which will be called upon to supply drugs no longer available from some of their rivals in India, analysts say.
Mar 21, 2014 at 14:03 | Source: Moneycontrol.com
Lupin announced today that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Niacin Extended Release Tablets USP, 500 mg, 750 mg, 1000 mg strengths having received final approval from the United States Food and Drug Administration (FDA) yesterday.
Messages on Fda »

radha123201
1

Platinum Member

1404 Followers

Just Posted  

and Drug Administration said on its website. The recall was initiated on Jan. 27 but made public by the FDA this week. The latest recall is for Lupin`s branded drug Suprax, the brand name for cefixime—an antibiotic used to treat bacterial infections of the ear and upper respiratory tract.

7.13 PM Apr 15th

venkatagopa
l

Platinum Member

343 Followers

Orchid Chemical  

Now Orchid is in a low margin business. The recent US fDA approval is only a RENEWAL not much of a great thing. Comparing Wock with Orchid is not a wise comparison. I dont intend to discourage you and tell that it is not a turnaround story. But, too early; there r no such signals of recovery. Let

1.34 PM Apr 15th

sathiboy

Gold Member

15 Followers

Orchid Chemical  

Considering company`s strong R&D pipeline ,I believe company can regain the reduced business in another few years .Recently U. S. health regulator Food & Drug Administration (FDA) inspected its Irungattukottai, Chennai-based oral formulations facility and approved it without any observations

12.50 PM Apr 15th

rishithegre
at

Platinum Member

84 Followers

Wockhardt  

at Rs. 650 it is hopelessly undervalued. Now there are two scenarios 1. The FDA woes continue. Even in such a situation I think Rs. 700 is a good valuation even if they maintain their current cash flows. 2. If they settle their FDA woes soon then when they get back to normal valuation and they start

4.03 PM Apr 14th

boarder77

Platinum Member

52 Followers

Biocon  

Akrmr - both state and KMS could be correct as the definition of `Operational` could mean different things to different groups. Malaysia might say that as the plant is ready it`s job done whereas for Biocon ready means FDA approved and shipment ready?

1.46 PM Apr 14th

shiv_analys
t

Platinum Member

183 Followers

Wockhardt  

Says Sarabjit Kour Nangra, vice-president for pharmaceutical research, Angel Broking: "Nothing substantial has come out of the development. The FDA needs to approve this and, till then, I don`t read much into this news development. However, the markets are expecting the FDA to take steps that could

11.07 PM Apr 13th

11san

New Member

0 Follower

Wockhardt  

looks like US FDA approvals not very far. Big boys are getting ready for 2500 figure.

1.15 PM Apr 11th

la4440

Platinum Member

36 Followers

Ranbaxy Labs  

Good news trickles in for Ranbaxy, FDA approves Gurgaon & Romania R&D centres

11.37 PM Apr 10th

elkot

Gold Member

10 Followers

Ranbaxy Labs  

ranbaxy passed all negative of fda alerts, no down trend from this level. buy for a target of 650 in three month.( sun pharma also trading 600 .( assume 1:1 swap ratio of merger of two companies)

7.55 PM Apr 10th

avema14

New Member

2 Followers

Ranbaxy Labs  

Ranbaxy rallies over 3% intraday as FDA approves Gurgaon & Romania R&D centres Read more at economic times

7.25 PM Apr 10th

News across the web »
Apr 15, 2014 at 04:57 | Source: Calcutta Telegraph News
Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.